Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06775041 · ClinicalTrials.gov registry record · Phase 2
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
A Phase 2 study of Hutchinson-Gilford Progeria Syndrome, sponsored by PRG Science & Technology Co..
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06775041 is a Phase 2 study of Hutchinson-Gilford Progeria Syndrome that is active but no longer recruiting, run by PRG Science & Technology Co.. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06775041, a Phase 2 study of Hutchinson-Gilford Progeria Syndrome, is active but no longer recruiting, sponsored by PRG Science & Technology Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.
Conditions Studied
Interventions
- DRUG Progerinin
- DRUG Lonafarnib
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06775041
The ClinicalTrials.gov registry entry for NCT06775041 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PRG Science & Technology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hutchinson-Gilford Progeria Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Progerinin is the first listed.
NCT06775041 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06775041 about?
NCT06775041 is a clinical study titled "Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)". Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (...
What is the current status of trial NCT06775041?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-01-13. Estimated completion is 2026-03.
What conditions does trial NCT06775041 study?
This clinical trial studies the following conditions: Hutchinson-Gilford Progeria Syndrome.
What interventions are being tested in trial NCT06775041?
The interventions under investigation include: Progerinin (DRUG), Lonafarnib (DRUG).
Who is sponsoring clinical trial NCT06775041?
This trial is sponsored by PRG Science & Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06775041 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hutchinson-Gilford Progeria Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.